N.Y. AG sets sights on Forest trials
Executive Summary
New York Attorney General Eliot Spitzer issues a request to Forest for information related to off-label clinical trials and promotion of its products, company says June 29. The AG is "concerned that Forest may be in violation of New York state law"; Forest maintains it has been in compliance with all applicable laws. Spitzer recently brought suit against GlaxoSmithKline, alleging the company concealed results from pediatric studies of its antidepressant Paxil (1"The Pink Sheet" June 7, 2004, p. 3). Forest issued a press release reiterating the results of Celexa and Lexapro pediatric studies after the Paxil suit was filed (2"The Pink Sheet" June 28, 2004, p. 30)...
You may also be interested in...
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.